These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 39044246)
1. Psychological distress following multi-gene panel testing for hereditary breast and ovarian cancer risk. Carlsson L; Bedard PL; Kim RH; Metcalfe K J Genet Couns; 2024 Jul; ():. PubMed ID: 39044246 [TBL] [Abstract][Full Text] [Related]
2. Psychological and health behaviour outcomes following multi-gene panel testing for hereditary breast and ovarian cancer risk: a mini-review of the literature. Carlsson L; Thain E; Gillies B; Metcalfe K Hered Cancer Clin Pract; 2022 Jun; 20(1):25. PubMed ID: 35733200 [TBL] [Abstract][Full Text] [Related]
3. Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients. Culver JO; Ricker CN; Bonner J; Kidd J; Sturgeon D; Hodan R; Kingham K; Lowstuter K; Chun NM; Lebensohn AP; Rowe-Teeter C; Levonian P; Partynski K; Lara-Otero K; Hong C; Morales Pichardo J; Mills MA; Brown K; Lerman C; Ladabaum U; McDonnell KJ; Ford JM; Gruber SB; Kurian AW; Idos GE Cancer; 2021 Apr; 127(8):1275-1285. PubMed ID: 33320347 [TBL] [Abstract][Full Text] [Related]
4. Impact of Panel Gene Testing for Hereditary Breast and Ovarian Cancer on Patients. Lumish HS; Steinfeld H; Koval C; Russo D; Levinson E; Wynn J; Duong J; Chung WK J Genet Couns; 2017 Oct; 26(5):1116-1129. PubMed ID: 28357778 [TBL] [Abstract][Full Text] [Related]
5. Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across Spain. Esteban I; Vilaró M; Adrover E; Angulo A; Carrasco E; Gadea N; Sánchez A; Ocaña T; Llort G; Jover R; Cubiella J; Servitja S; Herráiz M; Cid L; Martínez S; Oruezábal-Moreno MJ; Garau I; Khorrami S; Herreros-de-Tejada A; Morales R; Cano JM; Serrano R; López-Ceballos MH; González-Santiago S; Juan-Fita MJ; Alonso-Cerezo C; Casas A; Graña B; Teulé A; Alba E; Antón A; Guillén-Ponce C; Sánchez-Heras AB; Alés-Martínez JE; Brunet J; Balaguer F; Balmaña J Psychooncology; 2018 Jun; 27(6):1530-1537. PubMed ID: 29498768 [TBL] [Abstract][Full Text] [Related]
6. Reflex BRCA1 and BRCA2 tumour genetic testing for high-grade serous ovarian cancer: streamlined for clinicians but what do patients think? McCuaig JM; Ferguson SE; Vicus D; Ott K; Stockley TL; Kim RH; Metcalfe KA Hered Cancer Clin Pract; 2022 Apr; 20(1):15. PubMed ID: 35418215 [TBL] [Abstract][Full Text] [Related]
7. Psychosocial problems in women attending French, German and Spanish genetics clinics before and after targeted or multigene testing results: an observational prospective study. Brédart A; Kop JL; Dick J; Cano A; De Pauw A; Anota A; Brunet J; Devilee P; Stoppa-Lyonnet D; Schmutzler R; Dolbeault S BMJ Open; 2019 Sep; 9(9):e029926. PubMed ID: 31551380 [TBL] [Abstract][Full Text] [Related]
8. Prevalence of pathogenic variants and variants of unknown significance in patients at high risk of breast cancer: A systematic review and meta-analysis of gene-panel data. van Marcke C; Collard A; Vikkula M; Duhoux FP Crit Rev Oncol Hematol; 2018 Dec; 132():138-144. PubMed ID: 30447919 [TBL] [Abstract][Full Text] [Related]
9. Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing. Chang J; Seng S; Yoo J; Equivel P; Lum SS Ann Surg Oncol; 2019 Oct; 26(10):3389-3396. PubMed ID: 31342386 [TBL] [Abstract][Full Text] [Related]
10. Patient-reported outcomes associated with reflex BRCA1/2 tumor and subsequent germline panel genetic testing for high-grade serous ovarian cancer. McCuaig JM; Stockley TL; Ferguson SE; Vicus D; Brennenstuhl S; Ott K; Kim RH; Metcalfe KA J Genet Couns; 2023 Apr; 32(2):503-513. PubMed ID: 36478486 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of a 27-gene inherited cancer panel across 630 consecutive patients referred for testing in a clinical diagnostic laboratory. Gardner SA; Weymouth KS; Kelly WS; Bogdanova E; Chen W; Lupu D; Suhl J; Zeng Q; Geigenmüller U; Boles D; Okamoto PM; McDowell G; Hayden MA; Nagan N Hered Cancer Clin Pract; 2018; 16():1. PubMed ID: 29308099 [TBL] [Abstract][Full Text] [Related]
12. Economic impact of multigene panel testing for hereditary breast and ovarian cancer. Byfield SD; Wei H; DuCharme M; Lancaster JM J Comp Eff Res; 2021 Feb; 10(3):207-217. PubMed ID: 33491479 [No Abstract] [Full Text] [Related]
13. Rescreening for genetic mutations using multi-gene panel testing in patients who previously underwent non-informative genetic screening. Frey MK; Kim SH; Bassett RY; Martineau J; Dalton E; Chern JY; Blank SV Gynecol Oncol; 2015 Nov; 139(2):211-5. PubMed ID: 26296696 [TBL] [Abstract][Full Text] [Related]
15. An update on genetic risk assessment and prevention: the role of genetic testing panels in breast cancer. Piccinin C; Panchal S; Watkins N; Kim RH Expert Rev Anticancer Ther; 2019 Sep; 19(9):787-801. PubMed ID: 31469018 [No Abstract] [Full Text] [Related]
16. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients. Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208 [TBL] [Abstract][Full Text] [Related]
17. Patients' Medical and Psychosocial Experiences After Detection of a Hamilton JG; Long JM; Brandt AC; Brower J; Symecko H; Salo-Mullen EE; Christian SN; Harstad T; Couch FJ; Garber JE; Offit K; Robson ME; Domchek SM JCO Precis Oncol; 2019; 3():. PubMed ID: 31511843 [TBL] [Abstract][Full Text] [Related]
18. Next step in molecular genetics of hereditary breast/ovarian cancer: Multigene panel testing in clinical actionably genes and prioritization algorithms in the study of variants of uncertain significance. Castillo-Guardiola V; Rosado-Jiménez L; Sarabia-Meseguer MD; Marín-Vera M; Macías-Cerrolaza JA; García-Hernández R; Zafra-Poves M; Sánchez-Henarejos P; Moreno-Locubiche MÁ; Cuevas-Tortosa E; Arnaldos-Carrillo M; Ayala de la Peña F; Alonso-Romero JL; Noguera-Velasco JA; Ruiz-Espejo F Eur J Med Genet; 2022 Apr; 65(4):104468. PubMed ID: 35245693 [TBL] [Abstract][Full Text] [Related]
19. How to facilitate psychosocial adjustment in women tested for hereditary breast or ovarian cancer susceptibility? Insights from network analysis. Brédart A; Dick J; Cano A; Robieux L; De Pauw A; Schmutzler R; Stoppa-Lyonnet D; Dolbeault S; Kop JL Psychooncology; 2020 Mar; 29(3):550-556. PubMed ID: 31823434 [TBL] [Abstract][Full Text] [Related]
20. Management of ovarian and breast cancer risk in non-BRCA HBOC pathogenic variant carriers in a large California health care system. Powell CB; Laurent C; Garcia C; Hoodfar E; Karlea A; Kobelka C; Lee J; Roh J; Kushi LH Gynecol Oncol; 2022 Dec; 167(3):467-475. PubMed ID: 36220669 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]